Abstract
Among all tumors of the Central Nervous System (CNS), Glioblastoma Multiforme (GBM) is the most aggressive and resistant to standard treatments. Despite many studies, the mean survival of patients is only 15 months. Within the tumor mass, there are groups of cells that have features of stem/progenitor cells, named glioblastoma stem cells (GSCs) and possess large potential for proliferatio…